Literature DB >> 2570233

Effect of non-steroidal anti-inflammatory drugs on the course of osteoarthritis.

S Rashad1, P Revell, A Hemingway, F Low, K Rainsford, F Walker.   

Abstract

To test the hypothesis that non-steroidal anti-inflammatory drugs (NSAIDs) accelerate the progression of osteoarthritis by reducing synthesis of vasodilator prostaglandins, thereby diminishing joint perfusion, 105 osteoarthritis patients awaiting hip arthroplasty were treated prospectively with a strong or weak prostaglandin synthesis inhibitor, indomethacin or azapropazone, respectively. Pain and radiological joint space were monitored during the period up to arthroplasty and the condition of the excised femoral head was determined. As judged by radiological and histopathological data, the two treatment groups were at a similar pathophysiological end-point when they came to arthroplasty. In the indomethacin group the affected hips lost joint space more rapidly than did the contralateral hips, a difference not seen in the azapropazone group. The patients receiving azapropazone, who had higher concentrations of synovial vasodilator prostaglandins, took longer than the indomethacin group to reach the arthroplasty end-point. Potent inhibitors of prostaglandin synthesis may be inappropriate in the management of osteoarthritis of the hip.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2570233     DOI: 10.1016/s0140-6736(89)90651-x

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  48 in total

Review 1.  Drug-induced rheumatic disorders: incidence, prevention and management.

Authors:  P Vergne; P Bertin; C Bonnet; C Scotto; R Trèves
Journal:  Drug Saf       Date:  2000-10       Impact factor: 5.606

2.  Key questions concerning paracetamol and NSAIDs for osteoarthritis.

Authors:  P Courtney; M Doherty
Journal:  Ann Rheum Dis       Date:  2002-09       Impact factor: 19.103

Review 3.  Interleukin-1, immune activation pathways, and different mechanisms in osteoarthritis and rheumatoid arthritis.

Authors:  B Kirkham
Journal:  Ann Rheum Dis       Date:  1991-06       Impact factor: 19.103

Review 4.  State-of-the-art disease-modifying osteoarthritis drugs.

Authors:  Roland W Moskowitz; Michele Hooper
Journal:  Curr Rheumatol Rep       Date:  2005-03       Impact factor: 4.592

Review 5.  A comparison of synovial fluid concentrations of non-steroidal anti-inflammatory drugs with their in vitro activity.

Authors:  E Urquhart
Journal:  Agents Actions       Date:  1991-03

Review 6.  The treatment of osteoarthritis.

Authors:  A C Jones; M Doherty
Journal:  Br J Clin Pharmacol       Date:  1992-04       Impact factor: 4.335

7.  Radiographic progression of hospital referred osteoarthritis of the hip.

Authors:  J Ledingham; S Dawson; B Preston; G Milligan; M Doherty
Journal:  Ann Rheum Dis       Date:  1993-04       Impact factor: 19.103

Review 8.  The evolution of nerve growth factor inhibition in clinical medicine.

Authors:  Barton L Wise; Matthias F Seidel; Nancy E Lane
Journal:  Nat Rev Rheumatol       Date:  2020-11-20       Impact factor: 20.543

Review 9.  Glucosamine: a review of its use in the management of osteoarthritis.

Authors:  Anna J Matheson; Caroline M Perry
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

10.  The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial.

Authors:  Allen D Sawitzke; Helen Shi; Martha F Finco; Dorothy D Dunlop; Clifton O Bingham; Crystal L Harris; Nora G Singer; John D Bradley; David Silver; Christopher G Jackson; Nancy E Lane; Chester V Oddis; Fred Wolfe; Jeffrey Lisse; Daniel E Furst; Domenic J Reda; Roland W Moskowitz; H James Williams; Daniel O Clegg
Journal:  Arthritis Rheum       Date:  2008-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.